Diligence memo · auto-generated · as of July 2, 2026
Vigeo Therapeutics, Inc.
Vigeo Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Vigeo Therapeutics, Inc. operates in Biotechnology, based in Cambridge.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vigeo Therapeutics, Inc. has raised $18M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.6M on 2021-03-15.
Most recent recorded round closed around 2021-03-15.
Valuation (modeled)modeled
Provath models Vigeo Therapeutics, Inc. at approximately $195M (range $8.3M–$903M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.08× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era. Within the normal band (108% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 35 months.
Last raise 5.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 66% of Biotechnology peers (4293 compared).
Modeled value ranks above 72% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.